These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 6706581

  • 21. [Cancer immunotherapy in dermatological view (author's transl)].
    Lübbe D, Gstöttner R.
    Arch Geschwulstforsch; 1980; 50(2):182-5. PubMed ID: 7436703
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Adjuvant therapy of malignant melanoma.
    Vosika GJ.
    Minn Med; 1979 Jul; 62(7):515-7. PubMed ID: 386072
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. [BCG vaccination].
    Kosunen T.
    Duodecim; 1974 Jul; 90(24):1709-11. PubMed ID: 4442342
    [No Abstract] [Full Text] [Related]

  • 26. [Unspecific, active BCG vaccination therapy in melanoma using a modified scarification procedure].
    Wolf M, Menzel W, Keller G.
    Dermatol Monatsschr; 1978 Apr; 164(4):302-3. PubMed ID: 668966
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Distant cutaneous granulomas after bacille Calmette-Guérin immunotherapy for malignant melanoma: case for direct infection.
    Moff SL, Corey GR, Gottfredsson M.
    Clin Infect Dis; 1999 Dec; 29(6):1569-70. PubMed ID: 10585816
    [No Abstract] [Full Text] [Related]

  • 29. BCG in cancer therapy: patient responses to BCG therapy for malignant melanoma.
    Sullivan BP.
    Am J Nurs; 1979 Feb; 79(2):320-4. PubMed ID: 254539
    [No Abstract] [Full Text] [Related]

  • 30. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
    Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, Shapiro RL, Harris MN, Roses DF.
    Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
    [Abstract] [Full Text] [Related]

  • 31. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
    Mordoh J, Kairiyama C, Bover L, Solarolo E.
    Medicina (B Aires); 1997 Jul; 57(4):421-7. PubMed ID: 9674264
    [Abstract] [Full Text] [Related]

  • 32. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients.
    Kölmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, Seebacher C, Botev IN, Niin M, Lambert D, Shafir R, Kokoschka EM, Kleeberg UR, Gefeller O, Pfahlberg A.
    Eur J Cancer; 2005 Jan; 41(1):118-25. PubMed ID: 15617996
    [Abstract] [Full Text] [Related]

  • 33. Malignant melanoma in transplant patients: review of five cases.
    Laing ME, Moloney FJ, Kay EW, Conlon P, Murphy GM.
    Clin Exp Dermatol; 2006 Sep; 31(5):662-4. PubMed ID: 16780495
    [Abstract] [Full Text] [Related]

  • 34. [Use of immunotherapy in the treatment of malignant melanoma of the skin].
    Kristensen E.
    Ugeskr Laeger; 1976 Feb 16; 138(8):468-73. PubMed ID: 1258215
    [No Abstract] [Full Text] [Related]

  • 35. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS, Mastrangelo MJ, Sulit H, Chee D, Yarbro JW, Prehn LM, Prehn RT.
    Natl Cancer Inst Monogr; 1973 Dec 16; 39():213-20. PubMed ID: 4595320
    [No Abstract] [Full Text] [Related]

  • 36. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic allogeneic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma.
    Elliott GT, McLeod RA, Perez J, Von Eschen KB.
    Semin Surg Oncol; 1993 Dec 16; 9(3):264-72. PubMed ID: 8516615
    [Abstract] [Full Text] [Related]

  • 37. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE, Weber RW, Allen RE, Meyer J, Cruickshank S, Garbe E, Lin HY, Soong SJ.
    J Immunother; 2009 Dec 16; 32(6):632-7. PubMed ID: 19483646
    [Abstract] [Full Text] [Related]

  • 38. Bcg and autoimmunity: another two-edged sword.
    Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M.
    J Autoimmun; 2001 May 16; 16(3):235-40. PubMed ID: 11334488
    [Abstract] [Full Text] [Related]

  • 39. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A, Beyríe Tamayo W, Gozá León F, Muñoz YI.
    Arch Esp Urol; 2004 May 16; 57(6):606-18. PubMed ID: 15382436
    [Abstract] [Full Text] [Related]

  • 40. Erythema multiforme as a complication of BCG scarification technique.
    Tschen EH, Jessen RT, Robertson G, Becker LE.
    Arch Dermatol; 1979 May 16; 115(5):614-5. PubMed ID: 443840
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.